title: Activation dependent and independent VLA-4 binding sites on vascular cell adhesion molecule-1.
abstract: Vascular cell adhesion molecule-1 (VCAM) is a cytokine-inducible member of the immunoglobulin superfamily which binds to the integrin VLA-4. VCAM is expressed predominantly on the vascular endothelium where it is involved in the recruitment of mononuclear cells and lymphocytes to sites of inflammation. Two forms of VCAM containing six and seven Ig domains (VCAM-6d; VCAM-7d) are generated by alternative splicing but the physiological significance of this is unknown. We have utilised VCAM deletion mutants, VCAM-transfected cell lines and monoclonal antibodies to assess the functional importance of the individual VCAM domains. We have identified two binding sites on VCAM-7d located in domains 1 and 4 that are involved in the adhesion of the U937 human myelomonocytic cell line. Adhesion to domain 1 is temperature-independent, inhibited by the anti-VCAM mAbs 4B2 or lE10, and insensitive to PMA activation. In contrast, adhesion to domain 4 is temperature sensitive, unaffected by mAbs 4B2 or lE10 and augmented by PMA. Adhesion to both domains can be totally inhibited by the anti-VLA-4 mAb, 2B4. The anti-VCAM mAb 4B2 inhibits adhesion of U937 cells to stably transfected VCAM-7d-CHO cells at 4 degrees C, but, at 37 degrees C the effect of 4B2 on adhesion is modest with incubation times of less than 60 minutes duration. With longer incubation times, its effectiveness gradually increases, so that by 2 hours > 75% of the response can be blocked. Co-incubation with PMA prevents this time-dependent enhancement of 4B2 efficacy but has no significant effect on the inhibitory activity of the anti-VLA-4 mAb 2B4. These data can be explained by postulating a two stage ligand-receptor interaction that involves activation-induced changes in the avidity of VLA-4 for domain 4 of VCAM.
authors.affiliation: British Bio-technology Limited, Oxford, U.K.
authors.forename: L A
authors.initials: LA
authors.lastname: Needham
authors.forename: S
authors.initials: S
authors.lastname: Van Dijk
authors.forename: R
authors.initials: R
authors.lastname: Pigott
authors.forename: R M
authors.initials: RM
authors.lastname: Edwards
authors.forename: M
authors.initials: M
authors.lastname: Shepherd
authors.forename: I
authors.initials: I
authors.lastname: Hemingway
authors.forename: L
authors.initials: L
authors.lastname: Jack
authors.forename: J M
authors.initials: JM
authors.lastname: Clements
mesh_terms: D017398:Alternative Splicing; D000818:Animals; D000911:Antibodies, Monoclonal / Q000302:isolation & purification; D001665:Binding Sites; D016466:CHO Cells / Q000378:metabolism; D002448:Cell Adhesion / Q000502:physiology; D015815:Cell Adhesion Molecules / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D002460:Cell Line; D006224:Cricetinae; D004926:Escherichia coli / Q000235:genetics; D006801:Humans; D039041:Integrin alpha4beta1; D016023:Integrins / Q000276:immunology / Q000378:metabolism*; D007700:Kinetics; D051379:Mice; D016297:Mutagenesis, Site-Directed; D016029:Receptors, Very Late Antigen / Q000276:immunology / Q000378:metabolism*; D017384:Sequence Deletion; D019010:Vascular Cell Adhesion Molecule-1
chemical_list: D000911:Antibodies, Monoclonal; D015815:Cell Adhesion Molecules; D039041:Integrin alpha4beta1; D016023:Integrins; D016029:Receptors, Very Late Antigen; D019010:Vascular Cell Adhesion Molecule-1